$CSTL News

Castle Biosciences to Release Third Quarter 2026 Financial Results and Host Webcast on Thursday, Nov. 5, 2026

ACG 2026 Data Show TissueCypher® Identifies Elevated Risk of Progression Beyond Pathology Findings in Barrett's Esophagus

Castle Biosciences To Present New Data From Three Studies Evaluating Its TissueCypher Barrett's Esophagus Test At ACG 2026 Annual Scientific Meeting And Postgraduate Course

New Melanoma Study Backing DecisionDx-Melanoma Could Be A Game Changer For Castle Biosciences (CSTL)

Late-Breaking EADV 2026 Data Support Use of DecisionDx®-Melanoma in SLNB Decision-Making and Risk-Aligned Post Surgical Management

Castle Biosciences To Present New Data On DecisionDx-Melanoma At EADV Congress 2026

New Study Shows That TissueCypher® Changed Management at an Expert Surgery Center in 90% of Patients With Non-Dysplastic Barrett's Esophagus

New Study Highlights Clinical Need for Molecular Guidance in Atopic Dermatitis Treatment Selection, Reinforcing the Value of AdvanceAD-Tx™

Castle Biosciences Announces Publication Of New Study Highlighting Demand For Molecular Testing In Atopic Dermatitis

Castle Biosciences to Open New Laboratory Facility in Scottsdale

Castle Biosciences Announces Opening Of New Laboratory And Office Facility In Scottsdale, Arizona

New Decision Modeling Study Demonstrates TissueCypher® Significantly Improves Risk-Aligned Management for Patients with Barrett's Esophagus

JAAD Publication Shows Improved Performance of DecisionDx®-SCC

Castle Biosciences, Inc. (CSTL) Is Up 15.46% in One Week: What You Should Know

Castle Biosciences (CSTL) Rallies On Earnings Optimism, Is The Stock Still Cheap?

Does Castle Biosciences (CSTL) Have the Potential to Rally 31.46% as Wall Street Analysts Expect?

Castle Biosciences to Participate in Upcoming Investor Conferences

Castle Biosciences Approved for Dual Listing on Nasdaq Texas

Castle Biosciences Raises Outlook as Melanoma, TissueCypher Tests Gain Traction

BTIG Maintains Buy on Castle Biosciences, Raises Price Target to $44